MAP2K7 and ovarian carcinoma: In addition, other histotype-specific management strategies are now being adopted or investigated in ovarian cancer, including MEK inhibition for low-grade serous ovarian carcinoma and immunotherapy for clear cell ovarian carcinoma (2).